Fast Five Quiz: Myelodysplastic Syndrome Pathology

Emmanuel C. Besa, MD

Disclosures

May 12, 2021

The National Comprehensive Cancer Network (NCCN) utilizes the World Health Organization (WHO) classification system for diagnosis and distinguishes subtypes on the basis of blood and bone marrow findings; the criteria for MDS-RS are:

  • Blood: anemia, no blasts;

  • Bone marrow: ≥ 15% of erythroid precursors with ring sideroblasts or ≥ 5% ring sideroblasts if SF3B1 mutation is present

Patients with less than 5% bone marrow blasts who have 1% blasts in the peripheral blood documented on at least two separate occasions would be considered to have MDS-U.

Learn more about MDS guidelines.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....